Loading…
Actinium Pharmaceuticals, Inc. is projected to rise to $1.23 by 2027, a +4% move from its current price of $1.18. ATNM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.14 | $1.18 | $1.22 | 0.00% |
| May 30 | $1.13 | $1.18 | $1.24 | 0.00% |
| May 31 | $1.12 | $1.18 | $1.25 | 0.00% |
| Jun 1 | $1.11 | $1.18 | $1.26 | 0.00% |
| Jun 2 | $1.10 | $1.18 | $1.27 | 0.00% |
| Jun 3 | $1.09 | $1.18 | $1.28 | 0.00% |
| Jun 4 | $1.08 | $1.18 | $1.29 | 0.00% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.08 | $1.18 | $1.29 | 0.00% |
| Week 2 | $1.05 | $1.18 | $1.33 | +0.01% |
| Week 3 | $1.02 | $1.18 | $1.37 | +0.01% |
| Week 4 | $0.995 | $1.18 | $1.40 | +0.01% |
| Week 5 | $0.9752 | $1.18 | $1.43 | +0.01% |
| Week 6 | $0.9577 | $1.18 | $1.45 | +0.02% |
| Week 7 | $0.9418 | $1.18 | $1.48 | +0.02% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease.
It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications.
The company is based in New York, New York.
ATNM operates in the Healthcare sector and is currently priced at $1.18. Its market capitalization is $37.02M and it ranks 4721 by market cap.
The stock’s price outlook is informed by a year-by-year forecast that shows gradual upside over time. The forecast starts with a 2026 average of $1.18 and progresses toward higher long-term values, with a 2050 average of $4.42 and a 2050 maximum of $8.91. Early-year ROIs are modest or flat, with stronger upside emerging in later years (e.g., 21% in 2031, 58.8% in 2032, and 274.5% in 2050).
Overall sentiment shifts from neutral in the near term to bullish in the longer term.
A major floor 27.1% below — a decisive break under it would weaken the trend.
The nearest floor, 5.9% below — buyers have tended to step in here.
The nearest ceiling, 28.8% above — a clean break opens room to run.
A major ceiling 42.4% above — clearing it would confirm fresh momentum.
Key ATNM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ATNM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.17 | Buy | $1.18 | Buy |
| MA 10 | $1.20 | Sell | $1.19 | Sell |
| MA 20 | $1.21 | Sell | $1.21 | Sell |
| MA 50 | $1.18 | Sell | $1.21 | Sell |
| MA 100 | $1.20 | Sell | $1.24 | Sell |
| MA 200 | $1.36 | Sell | $1.37 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.67 | Neutral |
| Stoch RSI (14) | 21.24 | Neutral |
| CCI (20) | -41.11 | Neutral |
| Williams %R (14) | -84.21 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -9.92 | Sell |
| Bollinger %B (20,2) | 0.36 | Neutral |
| Stochastic %K (14) | 15.79 | Buy |
| TRIX (15) | 0.06 | Buy |
| Awesome (5,34) | -0.06 | Sell |
| Ultimate (7,14,28) | 35.69 | Neutral |
| Momentum (10) | -0.12 | Sell |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 1.16 | Buy |
| ADX (14) | 11.03 | Neutral |
| ATR (14) | 0.03 | Info |
Market data indicate a neutral near-term picture. The RSI(14) is 50 and the sentiment is NEUTRAL, with a 50-day simple moving average of $1.18 and a 200-day simple moving average of $1.37.
In the near term, support is at $1.10 and resistance at $1.52. The 30-day trading range spans from $0.9437 up to $1.48, reflecting a narrow trading band around the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.98 | $1.18 | $1.57 | 0% | Neutral | |
| $0.9594 | $1.23 | $1.68 | +4% | Neutral | |
| $0.893 | $1.18 | $1.69 | 0% | Neutral | |
| $0.9731 | $1.33 | $1.95 | +12% | Neutral | |
| $0.9381 | $1.31 | $1.98 | +11% | Neutral | |
| $1.03 | $1.48 | $2.29 | +25% | Bullish | |
| $1.32 | $1.92 | $3.04 | +63% | Bullish | |
| $1.28 | $1.91 | $3.08 | +62% | Bullish | |
| $1.24 | $1.88 | $3.09 | +59% | Bullish | |
| $1.28 | $1.97 | $3.29 | +67% | Bullish | |
| $1.77 | $2.97 | $5.31 | +152% | Bullish | |
| $2.43 | $4.74 | $9.36 | +302% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.98 | $1.18 | $1.39 | +0.00% |
| June 2026 | $0.9983 | $1.18 | $1.42 | -0.25% |
| July 2026 | $0.9913 | $1.18 | $1.45 | +0.29% |
| August 2026 | $1.03 | $1.23 | $1.54 | +4.53% |
| September 2026 | $1.03 | $1.25 | $1.57 | +1.22% |
| October 2026 | $0.9944 | $1.21 | $1.53 | -3.25% |
| November 2026 | $0.9836 | $1.20 | $1.54 | -0.56% |
| December 2026 | $0.991 | $1.22 | $1.57 | +1.25% |
Click any year to see its month-by-month ATNM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ATNM is projected to trade between $0.98 and $1.57, averaging $1.18 — a potential gain of 0% from today's $1.18. A consolidation phase looks the most probable path here.
Actinium Pharmaceuticals, Inc.'s 2027 outlook centres on $1.23, within a $0.9594 to $1.68 range. That is up +4% on the projected 2026 average. That marks a +4% change versus current levels. Price action looks broadly range-bound.
By 2028, ATNM could reach as high as $1.69, with a base case around $1.18 and support toward $0.893 — roughly 0% from $1.18. A consolidation phase looks the most probable path here.
Expect ATNM to range from $0.9731 to $1.95 through 2029. The $1.33 average target implies a +12% move from current prices. That is up +12% on the projected 2028 average. Price action looks broadly range-bound.
The ATNM price prediction for 2030 points to an average of $1.31 (low $0.9381, high $1.98) — a potential gain of +11% on today's $1.18. A consolidation phase looks the most probable path here.
In 2031, ATNM is projected to trade between $1.03 and $2.29, averaging $1.48 — a potential gain of +25% from today's $1.18. That is up +13% on the projected 2030 average. Momentum favours further upside here.
Actinium Pharmaceuticals, Inc.'s 2032 outlook centres on $1.92, within a $1.32 to $3.04 range. That is up +30% on the projected 2031 average. That marks a +63% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, ATNM could reach as high as $3.08, with a base case around $1.91 and support toward $1.28 — roughly +62% from $1.18. Momentum favours further upside here.
Expect ATNM to range from $1.24 to $3.09 through 2034. The $1.88 average target implies a +59% move from current prices. That is -1% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The ATNM price prediction for 2035 points to an average of $1.97 (low $1.28, high $3.29) — a potential gain of +67% on today's $1.18. Momentum favours further upside here.
In 2040, ATNM is projected to trade between $1.77 and $5.31, averaging $2.97 — a potential gain of +152% from today's $1.18. That is up +50% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Actinium Pharmaceuticals, Inc.'s 2050 outlook centres on $4.74, within a $2.43 to $9.36 range. That is up +60% on the projected 2040 average. That marks a +302% change versus current levels. Momentum favours further upside here.
Investing $1,000 in ATNM today (≈ 847.457627 ATNM) could be worth
$4,017.54
+$3,017.54 (+302%) by 2050 · US Dollar
Based on the average projected ATNM price of $4.74 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ATNMwould be worth at today's price.
$1,000 invested in ATNM on May 27, 2025 (≈ 606.060615 ATNM) would be worth
$715.15
-$284.85 (-28.5%) today · 0.72× · US Dollar
Based on a ATNM entry price of $1.65 vs. today's $1.18.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.17 | $1,008.55 | +0.9% |
| 1 month ago | $1.21 | $975.21 | -2.5% |
| 3 months ago | $1.15 | $1,026.09 | +2.6% |
| 6 months ago | $1.38 | $855.07 | -14.5% |
| 1 year ago | $1.65 | $715.15 | -28.5% |
| All time (5.0y) ago | $8.63 | $136.73 | -86.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ATNM forecast.
Our base-case forecast reaches $2.40 around 2040.
Implied market cap at $2.40: $75.3M
The multi-year forecast suggests meaningful upside over time, with the 2026 average at $1.18 and a 2030 average of $1.26. By 2031 the average rises to $1.43 and the 2032 average to $1.87, with the 2040 average at $2.86 and the 2050 average reaching $4.42. The implied maximums grow to $1.92 in 2030 and to $8.91 by 2050, underscoring substantial longer-run upside, though near-term dips are possible as indicated by a 2028 average of $1.17 and a -0.7% ROI that year.
ROI figures show a quiet start (0% in 2026, 2.9% in 2027) followed by higher returns in later years: 9.8% in 2029, 6.5% in 2030, then 21% in 2031, 58.8% in 2032, 55.8% in 2033, 53.6% in 2034, and 60.8% in 2035. The forecast accelerates further with 142.3% ROI in 2040 and 274.5% in 2050, with bullish sentiment from 2031 onward.
Tap a question to reveal the answer.
Avg $1.26, min $0.8898, max $1.92; roiPct 6.5; sentiment NEUTRAL.
Forecasts show a path to higher averages and double-digit ROI in several years (e.g., 21% in 2031, 58.8% in 2032, 55.8% in 2033, 142.3% in 2040, 274.5% in 2050), but near-term years also include flat or negative returns (0% in 2026, -0.7% in 2028). These are estimates, not guarantees.
Yes. The 2050 maximum is $8.91, which exceeds $5, indicating the potential for higher price levels under the forecast, though not guaranteed.
The 30-day range is $0.9437 to $1.48; RSI(14) = 50; SMA50 = $1.18; SMA200 = $1.37; near-term support $1.10 and resistance $1.52.
Current price $1.18; Market cap $37.02M.
Actinium Pharmaceuticals, Inc. Community Discussion
0Share your Actinium Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.